Physician profile
Michael A Pick
NPI 1861585846
$5,337.36
in general payments reported to CMS, 2019-2025
17 companies · $1,529 in 2025
The $1,529 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $252 · 2020: $111 · 2022: $474 · 2023: $1,483 · 2024: $1,489 · 2025: $1,529.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,362 · Education: $139.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,361.67 |
| Education | $139.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,513.28 | 2022-2025 | Krystexxa, Enbrel, Otezla |
| Abbvie INC. | $1,103.61 | 2019-2025 | |
| Horizon Therapeutics Plc | $493.04 | 2023 | Krystexxa |
| Ucb, INC. | $488.56 | 2023-2025 | Bimzelx, Cimzia |
| Astrazeneca Pharmaceuticals LP | $395.19 | 2022-2025 | Saphnelo |
| Janssen Biotech, INC. | $320.87 | 2022-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $291.83 | 2020-2025 | |
| Genentech USA, INC. | $142.29 | 2019 | |
| Genzyme Corporation | $140.70 | 2024-2025 | |
| Sandoz INC. | $123.10 | 2023-2025 | Hyrimoz |
| Fresenius Kabi USA, LLC | $90.78 | 2023-2025 | Idacio |
| Pfizer INC. | $66.93 | 2024-2025 | |
| Lilly USA, LLC | $47.83 | 2023 | Taltz |
| E.R. Squibb & Sons, L.L.C. | $44.40 | 2024 | Orencia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.94 | 2023 | Cyltezo |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $18.67 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $14.34 | 2023 | Iovera |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Pick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.